GLP1R and metabolic dysfunction-associated steatotic liver disease: Since GLP-1 receptor agonists reduce the risk of MALOs in patients with chronic liver disease and T2DM,27 while also reducing the risk of major adverse cardiovascular events,28 their use can be positioned at the nexus of both progressive MASLD and cardiac disease.